Home > Resources > Whitepapers > Improved Nucleic Acid QC with Parallel CE

Improved Nucleic Acid QC with Parallel CE

September 21, 2018

Nucleic acid quality assessment is a crucial step to the success or failure of DNA and RNA-based workflows. New methods and quality standards continually develop along with new applications. Whether for new sequencing chemistry, PCR strategy, or type of gene editing, understanding sample quality is essential for constructive outcomes. QC checkpoints help improve these diverse workflows, allowing researchers to work with only ideal samples. Not only are these checks important at the beginning of a workflow, but often are necessary throughout the process.

Spotlight

Enlumen Bio

Create superior customer experiences in the spectroscopy segment of the instrument market. Integrate the most current detection technologies with advanced interface devices to enable ease of use, elegant form factors, and strong value positions. Develop these improved products for accepted applications.

OTHER WHITEPAPERS

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Read More

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.

Read More

Application of Single-Use Technologies(SUT) in Biosimilar Development

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

Read More

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Read More

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.

Read More

Application of Single-Use Technologies(SUT) in Biosimilar Development

whitePaper | December 20, 2022

The current processing paradigm of large manufacturing facilities dedicated to singleproduct production is no longer an effective approach for best manufacturing practices.

Read More

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct
opportunities for tackling the urgent challenges before all humans

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

More Whitepapers

Spotlight

Enlumen Bio

Create superior customer experiences in the spectroscopy segment of the instrument market. Integrate the most current detection technologies with advanced interface devices to enable ease of use, elegant form factors, and strong value positions. Develop these improved products for accepted applications.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference